Abstract Introduction Treatments against urogenital cancers frequently have fertility side‐effects. The strategy to preserve fertility after oncologic treatments is still a matter of debate with a lack of evidence and international guidelines. The aim of this study is to investigate fertility preservation practices before urogenital cancer treatments and to compare national habits. Material and methods An online anonymous survey was submitted from January to June 2021 to six European urological societies. The 31‐items questionnaire included questions about demography, habits of evaluation, and management of fertility preservation in case of urogenital cancer treatments. Results Two hundred twenty‐eight urologists from six urological societies in five different countries (Belgium, The Netherlands, Luxembourg, France, Finland) filled out the survey. Three quarter (74%; n = 166) usually propose a cryopreservation before orchidectomy. In case of oligo/azoo‐spermia, the technique performed for the sperm extraction during orchidectomy varies among the sample: 70.5% ( n = 160) of the responders do not perform a Testicular Sperm Extraction (TESE) nor a Percutaneous Epididymal Sperm Aspiration (PESA). The cryopreservation for prostate cancer treatments is never proposed in 48.17% ( n = 105) of responders but conversely it is always proposed in 5.05% ( n = 11). The cryopreservation before bladder cancer treatments is not commonly proposed (67.5%, n = 154). Conclusion Our study showed variable country specific tendencies in terms of fertility preservation in the period of treatment of urological cancers. These differences seem to be related to national guidelines recommendations. Standardization of international guidelines is urgently needed in the field of fertility for urological cancer patients.